Genetics of Skin Cancer (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (07/14/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Squamous Cell Carcinoma

Added text about a double-blind, randomized, placebo-controlled trial in 14 patients with recessive dystrophic epidermolysis bullosa in which seven subjects were randomly assigned to receive an infusion of mesenchymal stem cells (MSCs) with cyclosporine and an additional seven subjects received only MSCs. The number of new blisters and the rate of blister healing were significantly improved in both groups. However, no difference was seen between the groups (cited El-Darouti et al. as reference 232).

Melanoma

Added text to state that a Spanish study of 531 melanoma cases and 499 population-based controls showed an odds ratio of 3.3 for melanoma in carriers of the E318K variant of the MITF gene. However, this study included melanoma cases from families with and without CDKN2A pathogenic variants. The prevalence of the MITF variant was similar in families with and without CDKN2A pathogenic variants (cited Potrony et al. as reference 166).

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Psychosocial Issues in Familial Melanoma

Next section >
About This PDQ Summary